No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OMCL Omnicell
- 27.400
- -0.460-1.65%
Close Apr 29 16:00 ET
1.26BMarket Cap-60888P/E (TTM)
28.361High27.190Low424.93KVolume27.900Open27.860Pre Close11.70MTurnover0.94%Turnover RatioLossP/E (Static)45.92MShares77.13552wk High1.06P/B1.24BFloat Cap25.69052wk Low--Dividend TTM45.23MShs Float187.285Historical High--Div YieldTTM4.21%Amplitude1.290Historical Low27.536Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), AnaptysBio (ANAB) and LivaNova (LIVN)
Automated Drug Kiosk Market Report 2024: Global Trends, Forecasts and Competitive Analysis to 2030 Featuring MedAvail, Smart RX Systems, Medifriend, Stericycle, Omnicell, ScriptPro, & PickPoint
Craig-Hallum Sticks to Its Buy Rating for Omnicell (OMCL)
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the
Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 34%?
Key Insights The projected fair value for Omnicell is US$39.89 based on 2 Stage Free Cash Flow to Equity Current share price of US$26.27 suggests Omnicell is potentially 34% undervalued The US$33
Omnicell (OMCL) Receives a Buy From Craig-Hallum
Comments
Omnicell stock is undervalued, presenting a buying opportunity. The company's future outlook is optimistic with robust cash flows expected to increase share value. However, consider other factors like financial health before investing.
Is Now The Time To Look At Buying Omnicell, Inc. (NASDAQ:OMCL)?The company's debt situation and EBIT loss of US$31m over the last twelve months raise concerns about its financial health. The balance sheet is considered far from match-fit and the stock is deemed very risky.
Omnicell's low P/S ratio suggests limited growth. Lackluster future revenue forecasts damages its value. Investors await improved performance as current weak outlook pressures stock price.
Given the falling EPS and poor performance over the last three years, future earnings performance is being considered critical for shareholders. Potential investors are cautioned to ensure they are investing in a high-quality business amid challenges.
The sharp cut to revenue forecasts suggests that investors should temper their expectations for Omnicell, Inc. Also, analysts anticipate slower revenue growth than the wider market, which could lead to increased caution among investors.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
